20 Feb Orchid Pharma shares in focus as U.S. FDA completes facility inspection
The inspection, conducted between February 10 and 18, resulted in seven minor observations but did not raise concerns about data integrity, the company said in a regulatory filing after market hours on Wednesday.
Orchid Pharma’s Alathur facility remains India’s only U.S. FDA-approved manufacturing site for sterile cephalosporins, a class of antibiotics used to treat bacterial infections.
“As India’s only U.S. FDA-approved facility for Sterile Cephalosporins, we take immense pride in maintaining this exclusive status that sets us apart in the global pharmaceutical landscape. The renewal of the EU GMP certificate further strengthens our position as a trusted pharmaceutical manufacturer for global markets,” said Manish Dhanuka, Managing Director, Orchid Pharma.
The company also announced that the facility has secured the renewal of its European Union Good Manufacturing Practice (EU GMP) certification, reinforcing compliance with European standards and enhancing its ability to serve key international markets.
According to Trendlyne data, the average consensus target price of the Orchid Pharma shares is Rs 1,545 per share, which implies an 85% potential upside from the current levels. Three out of the three analysts covering the stock recommend a “buy” rating. Orchid Pharma’s shares have been under pressure, falling 32.5% in the past week and 40.76% over the last six months. The stock closed 1.2% higher at Rs 828.25 on the BSE on Wednesday but remains down 24.76% over the past year.Also read | Gold and silver are God’s money, follow Rich Dad’s 3 rules: Robert Kiyosaki
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)